✦ LIBER ✦

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

✍ Scribed by Soria, Jean-Charles; Baselga, José; Hanna, Nasser; Laurie, Scott A.; Bahleda, Rastislav; Felip, Enriqueta; Calvo, Emiliano; Armand, Jean-Pierre; Shepherd, Frances A.; Harbison, Christopher T.; Berman, David; Park, Jong-Soon; Zhang, Steven; Vakkalagadda, Blisse; Kurland, John F.; Pathak, Ashutosh K.; Herbst, Roy S.

Book ID: 120232358
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 343 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.02.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, dose-finding study of AZD8931,

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

✍ Tjulandin, S.; Moiseyenko, V.; Semiglazov, V.; Manikhas, G.; Learoyd, M.; Saunde 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 313 KB

A phase I dose escalation study of BIBW

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Phase I and pharmacokinetic study of dac

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

✍ Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, Tateaki Naito, Asuka Tsuya 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 481 KB